Relationship of tumor necrosis factor-alpha and interleukin-10 with the development of fatal and non-fatal complications in patients with essential hypertension during mid-term follow-up

Objective. To study the association of tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) with the development of fatal and non-fatal complications in patients with essential hypertension (EHTN) in the process of mid-term follow-up.

Design and methods. 90 patients with EHTN aged 40 to 75 years (average age 56,4 ± 8,1 years) were observed, including 47 women and 43 men. The follow-up period ranged from 20 to 26 months (median observation — 24 months). At baseline, we assessed height, weight, body mass index, waist circumference, blood pressure and heart rate, fasting glucose, serum creatinine with the estimated glomerular filtration rate by CKD-EPI, lipid profile, serum levels of TNF-α and IL-10 by enzyme-linked immunosorbent tests (“CITOKIN — STIMUL — BEST”, Novosibirsk, Russia).

Results. A cumulative decrease in the proportion of patients with EHTN without development of fatal and non-fatal cardiovascular complications at follow-up was 70,73 %. When analyzing the associations between cytokines and the development of fatal and non-fatal complications in EHTN patients at term follow-up, we found no difference in TNF-α levels in EHTN patients who reached the end-point and patients without complications (8,31 ± 0,97 vs 8,37 ± 1,33 pg/ml, respectively, p > 0,05), while IL-10 level was higher in patients without complications compared to n patients with complicated EHTN (15,9 ± 3,3 vs 13,5 ± 2,3 pg/ml, respectively, p < 0,01). Logistic regression analysis showed that only systolic blood pressure was an independent risk factor associated with the development of EHTN complications during mid-term follow-up: hazard ratio (HR) — 1,03; 95 % confidence interval (CI) 1,00-1,05. In addition, an increase in IL-10 level was an independent anti-risk factor associated with a significant 25 % reduction in the risk of EHTN complications (HR 0,75; 95 % CI 0,57-0,99).

Conclusions. An increased IL-10 concentration was an independent anti-risk factor for the complicated EHTN during mid-term follow-up associated with a 25 % reduction in the risk of fatal and non-fatal complications. At the same time, we did not find the association of the TNF-α level with prognosis in EHTN patients during mid-term follow-up.

1. Wenzel U, Turner JE, Krebs C, Kurts C, Harrison D, Ehmke H. Immune mechanisms in arterial hypertension. J Am Soc Nephrol. 2016;27(3):677-686. Published Online. doi:10.1681/ASN.2015050562

2. Buko IV, Polonetsky IZ, Moiseenok AG. Erythrocyte glutatione and parameters of oxidative stress and inflammation in acute coronary syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(3):171-181. doi.org/10.18705/1607-419X-2014-20-3-172-181 In Russian.

3. Poredos P, SpirkoskaA, Lezaic L, Mijovski MB, Jezovnik MK. Patients with an inflamed atherosclerotic plaque have increased levels of circulating inflammatory markers. J Atheroscler Thromb. 2017;24(1):39-46. doi.org/10.5551/jat.34884

4. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483-493. doi:10.1111/joim.12406

5. Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail. 2008;10(1):63-69. doi.org/10.1016/j.ejheart.2007.11.003

6. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343 (16):1148-1155. doi:10.1056/NEJM200010193431603

7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18 (6):499-502.

8. Yao YS, Chang WW, Jin YL. Association between TNF-a promoter -308G/A polymorphism and essential hypertension in the Asian population: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2017;18(4):1470320317741066. doi:10.1177/1470320317741066

9. Kim KI, Lee JH, Chang HJ, Cho YS, Youn TJ, Chung WY et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J. 2008;72(2):293-298. doi:10.1253/circj.72.293

10. Pircher J, Merkle M, Wornle M, Ribeiro A, Czermak T, Stampnik Y et al. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther. 2012;14(5): R225. doi:10.1186/ar4064

11. Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res. 2016;167(1): 152-166. doi:10. 1016/j.trsl.2015.07.002

12. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91-112. doi:10.1161/CIRCRESAHA.116.303577

13. Shreider EV, Shakhnovich RM, Kaznacheyeva EI, Bosykh EG, Tkachev GA, Ruda MYa et al. Prognostic value of inflammatory markers and Nt-proBNP in different treatment options for patients with acute coronary syndrome. Cardiologicheskiy Vestnik. 2008;2;44-53. In Russian.

14. Volkova SYu. Prognostic value of measurement of plasma levels of neurohumoral mediators in subacute period of Q-Wave myocardial infarction. Kardiologiia. 2008;48(10):24-27. In Russian.

15. Zarrouk-Mahjoub S, Zaghdoudi M, Amira Z, Chebi H, Khabouchi N, Finsterer J et al. Pro- and anti-inflammatory cytokines in post-infarction left ventricular remodeling. Int J Cardiol. 2016;221:632-636.

16. Kovaleva ON, Ascheulova TV, Gerasimchuk NN. The relationship of immune activation and oxidative stress in patients with hypertension and their correction with combination antihypertensive therapy. Scientific Statements. 2015; 16;52-59. In Russian.

17. Mouco OM, Nicolau JC, Souza Tda R, Maia LN, Ramires JA. Inflammatory markers of atherosclerotic plaque stabilization after acute coronary event—temporal trends. Arq Bra Cardiol. 2006;87 (1):28-36.

18. Stumpf C, Seybold K, Petzi S, Wasmeier G, Raaz D, Yil-maz A et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail. 2008;10(8):733-739.

19. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol. 2009;135(3): 361-369.

20. Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J. 2010;12(3):158-162.

21. Ni SH, Sun SN, Huang ZY, Huang YS, Li H, Wang JJ et al. The pleiotropic association between IL-10 levels and CVD prognosis: Evidence from a meta-analysis. Cytokine. 2019;119:37-46.